Home › Funds › Bellevue Group AG › SYRE
Bellevue Group AG position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Bellevue Group AG reported holding 379,870 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$33.8M, representing 0.70% of its reported portfolio and ranking #38 among its reported holdings. Bellevue Group AG has disclosed SYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's SYRE position evolved
Bellevue Group AG first disclosed a stake in SYRE in Q2 2026 at 229,931 shares (US$20.4M). The position peaked in Q3 2026 at 379,870 shares, worth US$33.8M. Across 2 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 379,870 shares valued at US$33.8M — an increase of 149,939 shares quarter over quarter.. Notable position changes include a 65% increase in Q3 2026 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 229.93K | $20.41M | New |
| Q3 2026 | 379.87K | $33.82M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 68 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- Paradigm Biocapital Advisors LP 4.46M sh · $396.85M · Q3 2026
- RTW INVESTMENTS, LP 3.69M sh · $328.68M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.20M sh · $309.04M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M sh · $245.76M · Q3 2026
- Venrock Adviser, LLC 2.49M sh · $221.28M · Q3 2026
- TCG Crossover Management, LLC 1.90M sh · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $168.46M · Q3 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- BRAIDWELL LP 713.96K sh · $63.56M · Q3 2026
- Commodore Capital LP 700.00K sh · $62.32M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held SYRE?
Bellevue Group AG has disclosed SYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Bellevue Group AG's current position in SYRE?
As of Q3 2026, Bellevue Group AG holds 379.87K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $33.82M, representing 0.70% of its reported portfolio and ranking #38.
Has Bellevue Group AG been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Bellevue Group AG increased its position in SYRE. The position peaked in Q3 2026 at 379.87K shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.